Global Molecular Infectious Disease Testing Market OverviewThe global Molecular Infectious Disease Testing Market encompasses ...
Molecular Diagnostics Market is experiencing steady expansion, driven by the global shift toward rapid, decentralized, and ...
Q4 2025. Management View. CEO Joshua Riggs announced the submission of GraftAssureDx to the FDA, emphasizing, “ ...
Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) ...
Cardio Diagnostics Holdings (NASDAQ: CDIO) is an artificial intelligence-powered precision cardiovascular medicine company ...
The World Health Organization has called on countries to accelerate tuberculosis elimination efforts, unveiling new ...
A Ghanaian Scientist’s breakthrough research on fluorescent molecular probes could transform how the world detects cancer at ...
Students of Nagaland University attended a two-week National Skill Development and Hands-on Training Programme on Quality ...
The dangers for infection aren’t only caused by microbes, but also by the molecular signals they release. To detect and neutralize these signals, may be the next era for infectious disease control.” — ...
Tuberculosis (TB) is the world’s leading cause of death from a single infectious agent, affecting more than 10 million people ...
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q4 2025 Earnings Call Transcript March 26, 2026 Lucid Diagnostics Inc. misses on earnings expectations. Reported EPS is $-0.1 EPS, expectations were $-0.07.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results